Last reviewed · How we verify
NCT04651868
The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying
NA trial testing GLP-2 in Gallbladder in 15 participants. Completed in 27 April 2021.
27 April 2021
Quick facts
| Lead sponsor | University Hospital, Gentofte, Copenhagen |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 15 |
| Start date | 10 December 2020 |
| Primary completion | 27 April 2021 |
| Estimated completion | 27 April 2021 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
Conditions studied
- Gallbladder — all drugs for Gallbladder →
Sponsor
University Hospital, Gentofte, Copenhagen
Who can join
Adults 18 to 65, male only, with Gallbladder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a randomized, double-blinded, placebo-controlled, cross-over study, which will investigate the acute effects of the gut-derived hormone glucagon-like peptide 2 (GLP-2) on cholecystokinin (CCK)-induced gallbladder emptying. Furthermore, the investigators will investigate different hormonal responses and appetite during the study days. The investigators hypothesize that GLP-2 will overrule the potent gallbladder relaxing effect of CCK. We will include 15 healthy male participants, and each of the participants will participate in four study days. GLP-2 and CCK will be given intravenously, and will be placebo-controlled. Gallbladder volume will be determined by frequent ultrasonography scans. Appetite will be assessed by Visual Analog Scales through out the study day and an ad libitum meal at the end of the study day. Blood samples will be drawn at regular intervals to asses different hormonal responses.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exogenous Glucagon-like Peptide 2 Counteracts Exogenous Cholecystokinin-induced Gallbladder Contraction in Healthy Men.
Lange AH, Hansen NL, Pedersen MG, Nerild HH, et al · · 2024 · cited 4× · PMID 38888179 · DOI 10.1210/clinem/dgae421
Verify or expand the search:
- PubMed search for NCT04651868
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GLP-2
Trials testing the same drug.
- NCT03867656 — Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19 · NA · completed
- NCT03728959 — Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism. · NA · completed
- NCT03573934 — Gut Hormones and Bone Remodeling in Humans (KS-2) · NA · completed
Other recruiting trials for Gallbladder
Currently open trials in the same condition.
- NCT05169073 — Virtual Reality Training for Laparoscopic Cholecystectomy · NA · recruiting
Other University Hospital, Gentofte, Copenhagen trials
Trials by the same sponsor.
- NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
- NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
- NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
- NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
- NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04651868 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04651868.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing